

IMMUNOMEDICS INC
Form 8-K
February 27, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 27, 2013

Immunomedics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-12104
(Commission
File Number)

61-1009366
(IRS Employer
Identification No.)

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

300 The American Road, Morris Plains, New Jersey
(Address of Principal Executive Offices)

(973) 605-8200

07950
(Zip Code)

(Registrant's telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 8.01 Other Events

On February 27, 2013, Immunomedics, Inc., a Delaware corporation (the "Company"), issued a press release announcing that the Company has completed its previously announced sale of an aggregate of 6,086,956 shares of common stock pursuant to the Company's existing shelf registration statement (File No. 333-184377) on Form S-3. In addition, the Company announced the exercise of the underwriters' over-allotment option to purchase 913,044 shares of the Company's common stock. The sale of the additional shares by the Company upon the exercise of the over-allotment option also closed on February 27, 2013. In the aggregate, the Company received total proceeds of approximately \$14.8 million, based on a public offering price of \$2.30 per share, after deducting the underwriting discounts and commissions and estimated expenses related to the offering payable by the Company. Oppenheimer & Co. Inc. and Cowen and Company, LLC served as the joint book-running managers.

Item 9.01 Financial Statements and Exhibits.

Exhibits.

Exhibit No.	Description
99.1	Press Release of the Company dated February 27, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.

By: /s/ Cynthia L. Sullivan

Name: Cynthia L. Sullivan

Title: President and Chief Executive Officer

Date: February 27, 2013